Francesco Celi is an Endocrinology/Metabolic physician. OpenAlex indexes 167 publications with 8,783 citations (h-index 45); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
263 Farmington Avenue
Farmington, CT 06030
Telephone
860-679-6663Provider last certified this registry record 18 Jun 2025.
Clinical trials
- Novel Approaches to the Treatment of Hypothyroidism
Sponsor: UConn Health
- Maladaptive Adipose Tissue Activity in Cancer
Sponsor: Virginia Commonwealth University
- Effects of Liothyronine on Energy Expenditure and Cardiovascular Function
Sponsor: Virginia Commonwealth University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Xeris Pharmaceuticals, Inc.Program year20253 payments$11,959openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year20241 payment
- Xeris Pharmaceuticals, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
67.6%GLP-1 receptor agonist48.5%Ozempic55%Trulicity46%Part D<11 patientsInsulin Analog19.1%Lantus100%Part D<11 patientsHormonal (systemic)
32.4%l-Thyroxine32.4%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- New Approaches for the treatment of Hypothyroidism
University of Connecticut Sch of Med/dnt
FY2026$333,000R01DK140455 - New Approaches for the treatment of Hypothyroidism
University of Connecticut Sch of Med/dnt
FY2025$333,000R01DK140455 - New Approaches for the treatment of Hypothyroidism
University of Connecticut Sch of Med/dnt
FY2024$333,000R01DK140455
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”